Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Day-to-night longevity support
An injectable protocol targeting a specific injury, combined with oral dosing for systemic support, leverages the advantages of both approaches
Macrophages of the vascular wall can collect iron, and iron overload in turn causes macrophages to transition to an anti-inflammatory phenotype, which leads to inflammation, oxidative stress, and increased plaque formation
Measurement properties of the Vitiligo Impact Scale-22 (VIS-22), a vitiligo-specific quality-of-life instrument
Container type
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
US$ 22.93
US$ 21.91
US$ 29.23
US$ 20.24
US$ 27.58
US$ 23.49
US$ 21.27
US$ 29.31
US$ 25.29
US$ 20.10
US$ 26.41
